Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)

Carla L. Alves*, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel

*Kontaktforfatter

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

8 Downloads (Pure)

Abstrakt

The original HTML version of this Article was updated shortly after publication because the previous HTML version linked to an incorrect Transparent Peer Review file.

OriginalsprogEngelsk
Artikelnummer5588
TidsskriftNature Communications
Vol/bind12
Antal sider1
ISSN2041-1723
DOI
StatusUdgivet - 16. sep. 2021

Bibliografisk note

Publisher Copyright:
© 2021, The Author(s).

Fingeraftryk

Dyk ned i forskningsemnerne om 'Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (Nature Communications, (2021), 12, 1, (5112), 10.1038/s41467-021-25422-9)'. Sammen danner de et unikt fingeraftryk.

Citationsformater